Copyright
©The Author(s) 2016.
World J Gastroenterol. Nov 21, 2016; 22(43): 9571-9585
Published online Nov 21, 2016. doi: 10.3748/wjg.v22.i43.9571
Published online Nov 21, 2016. doi: 10.3748/wjg.v22.i43.9571
Table 2 Antiviral prophylaxis before and after liver transplantation for hepatitis B virus reinfection
| Patients with high risk of HBV reinfection[HBV-DNA ≥ 105 copies/mL or HBeAg(+)] | Patients with low risk of HBV reinfection[HBV-DNA < 105 copies/mL or HBeAg(-)] |
| Pre-LT: nucleoside analogues, qd 2-4 w | Pre-LT: nucleoside analogues, qd 0-2 w |
| Intraoperative: HBIG 4000 IU, iv | Intraoperative: HBIG 2000 IU, iv |
| Post-LT: HBIG 1000 IU, iv, qd, 1-7 d | Post-LT: HBIG 1000 IU, iv, qd, 1-7d |
| After 7 d, HBIG 1000 IU, iv, once a week; or HBIG 400 IU, im, qd or qod or twice a week. Adjust frequency of HBIG administration to reach target therapeutic concentration | After 7 d, HBIG 1000 IU, iv, once a week; or HBIG 400 IU, im, qd or qod or twice a week. Adjust frequency of HBIG administration to reach target therapeutic concentration |
| Target therapeutic concentration post-LT | Target therapeutic concentration post-LT |
| ≤ 6 mo post-LT: anti-HBs titer ≥ 500 IU/L | ≤ 6 mo post-LT: anti-HBs titer ≥ 300 IU/L |
| 6-12 mo post-LT: anti-HBs titer ≥ 200 IU/L | 6-12 mo post-LT: anti-HBs titer ≥ 200 IU/L |
| ≥ 12 mo post-LT: anti-HBs titer ≥ 100 IU/L | ≥ 12 mo post-LT: anti-HBs titer ≥ 100 IU/L |
- Citation: Zhang Q, Deng YL, Liu C, Huang LH, Shang L, Chen XG, Wang LT, Du JZ, Wang Y, Wang PX, Zhang H, Shen ZY. Diabetes mellitus may affect the long-term survival of hepatitis B virus-related hepatocellular carcinoma patients after liver transplantation. World J Gastroenterol 2016; 22(43): 9571-9585
- URL: https://www.wjgnet.com/1007-9327/full/v22/i43/9571.htm
- DOI: https://dx.doi.org/10.3748/wjg.v22.i43.9571